SEC Filing Summary: Ra Medical Systems, Inc. (RMED)
Business Context and Reporting Period
This Form 8-K, dated August 31, 2022, reports material events for Ra Medical Systems, Inc. (RMED), a Delaware corporation. The filing addresses a new equity sales agreement, the completion of a significant workforce reduction, and a deficiency notice regarding stock listing compliance. The company is currently pursuing a potential merger with Catheter Precision, Inc., though terms remain under negotiation.
Key Financial Metrics and Liquidity
The filing does not provide specific revenue, profit, or cash flow figures for the period. However, it discloses the following financial data points:
- Equity Offering: Entered into an At Market Issuance Sales Agreement to sell up to $7,600,000 of common stock.
- Transaction Costs: Agreed to pay a 3.0% commission on gross proceeds from the equity offering.
- Restructuring Costs: Total costs related to the reduction in force (severance and retention) incurred to date are approximately $741,000.
- Future Cash Outlays: Estimated additional cash outlays for the reduction in force are $3,000.
- Headcount: As of September 2, 2022, the company retained only 9 full-time employees following a reduction of approximately 85% of its workforce.
Material Changes and Events
Three primary material events are reported:
- Capital Raise: On September 2, 2022, the company engaged Ladenburg Thalmann & Co. Inc. to sell shares via an "at the market" offering. Proceeds are intended to fund the potential merger with Catheter Precision, Inc., clinical study follow-ups, and working capital.
- Workforce Reduction: The company completed a reduction in force initiated in June 2022. Approximately 65% of employees were terminated in June, with an additional 20% terminated between August 1 and September 2, 2022. The stated purpose was to preserve capital while reviewing strategic alternatives.
- Listing Deficiency: On August 31, 2022, the NYSE American issued a deficiency letter stating the company failed to meet continued listing standards due to a low share price (30-day average below $0.20).
Outlook, Risks, and Management Commentary
Merger Uncertainty: Management states that while the merger with Catheter Precision, Inc. is being pursued, there is no assurance it will be consummated. Terms are still under negotiation and may deviate from previously disclosed term sheets.
Delisting Risk: The company has until February 28, 2023, to regain compliance with NYSE American listing standards. Failure to do so could result in delisting proceedings. The company plans to address this via a potential reverse stock split, scheduled for a special meeting on September 20, 2022.
Consequences of Delisting: If delisted, the company anticipates trading on an over-the-counter market, which could lead to reduced liquidity, classification as a "penny stock," limited analyst coverage, and increased difficulty in raising future capital.
Investor Verification Checklist
- Verify the status and definitive terms of the proposed merger with Catheter Precision, Inc.
- Confirm the outcome of the special shareholder meeting scheduled for September 20, 2022, regarding the reverse stock split.
- Monitor the company's ability to raise capital through the new At Market Issuance Sales Agreement given the current low share price.
- Review the company's cash runway given the reduction to 9 employees and the cessation of significant operational activity.
- Check for any updates on the NYSE American compliance status prior to the February 28, 2023 deadline.